Cancer Therapeutic Targets

In the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the heels of these successes, innumerable new targets and new potential therapeutics are being developed by many different groups including government agencies, pharmaceutical companies, biotechnology companies, academic institutions, and individual investigators. Understanding the expanding universe of cancer therapies is therefore becoming impossible and no single source exists which serves as a reference for the involved parties. Further, the interested parties have vastly different areas of expertise, from focused laboratory based science, to clinical research, to corporate and regulatory oversight.

The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well.

Editorial Board:

• John L. Marshall (Editor in Chief), Department of Hematology and Oncology, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA
  
• Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
  
• Lee M. Ellis, Department of Surgical Oncology and Molecular & Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
  
• Louis M. Weiner, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington DC, USA
  
• Emanuel F Petricoin, Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Institute of Advanced Biomedical Research, Manassas, VA, USA
  
• Edward P. Gelmann, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, USA